Nuclear factor-kappa B mediates TRPV4-NO pathway involved in thermal hyperalgesia following chronic compression of the dorsal root ganglion in rats

Behav Brain Res. 2011 Aug 1;221(1):19-24. doi: 10.1016/j.bbr.2011.02.028. Epub 2011 Feb 26.

Abstract

The aim of this study was to test the hypothesis that nuclear factor-kappa B (NF-κB) is involved in TRPV4-NO pathway in thermal hyperalgesia following chronic compression of the dorsal root ganglion (DRG) (the procedure hereafter termed CCD) in rat. Intrathecal administration of two NF-κB inhibitors, pyrrolidine dithiocarbamate (PDTC; 10(-1) to 10(-2)M) and BAY (100-50 μM), both induced significantly dose-dependent increase in the paw withdrawal latency (PWL) and decrease in nitric oxide (NO) content in DRG when compared with control rats. Pretreatment with 4α-phorbol 12,13-didecanoate (4α-PDD, transient receptor potential vanilloid 4 (TRPV4) synthetic activator, 1 nm) attenuated the suppressive effects of PDTC (10(-1)M) and BAY (100 μM) on CCD-induced thermal hyperalgesia and NO production. In addition, Western blot analysis indicated that CCD rats exhibited nuclear NF-κB protein expression and low levels of cytoplasmic inhibitory-kappa B (I-κB) expression; the increase in NF-κB expression and decrease in I-κB expression were reversed after intrathecal injection of PDTC. In conclusion, our data suggested that NF-κB could be involved in TRPV4-NO pathway in CCD-induced thermal hyperalgesia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / pharmacology
  • Analgesics / therapeutic use*
  • Animals
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Ganglia, Spinal / drug effects
  • Ganglia, Spinal / metabolism
  • Ganglia, Spinal / physiopathology*
  • Hyperalgesia / drug therapy
  • Hyperalgesia / physiopathology*
  • I-kappa B Proteins / biosynthesis
  • I-kappa B Proteins / physiology
  • Male
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / biosynthesis
  • NF-kappa B / physiology*
  • Nerve Compression Syndromes / complications
  • Neuralgia / metabolism*
  • Nitric Oxide / metabolism*
  • Nitriles / pharmacology
  • Nitriles / therapeutic use
  • Phorbols / pharmacology
  • Pyrrolidines / pharmacology
  • Pyrrolidines / therapeutic use
  • Rats
  • Rats, Wistar
  • Signal Transduction / drug effects
  • Signal Transduction / physiology*
  • Sulfones / pharmacology
  • Sulfones / therapeutic use
  • TRPV Cation Channels / agonists*
  • Thiocarbamates / pharmacology
  • Thiocarbamates / therapeutic use

Substances

  • 3-(4-methylphenylsulfonyl)-2-propenenitrile
  • 4alpha-phorbol 12,13-didecanone
  • Analgesics
  • I-kappa B Proteins
  • NF-kappa B
  • Nitriles
  • Phorbols
  • Pyrrolidines
  • Sulfones
  • TRPV Cation Channels
  • Thiocarbamates
  • Trpv4 protein, rat
  • pyrrolidine dithiocarbamic acid
  • Nitric Oxide